IBRX (ImmunityBio, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IBRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-06 | Christobel Selecky | Director | MIXED | — | — |
| 2026-07-06 | Cheryl Cohen | Director | MIXED | — | — |
| 2026-07-01 | Christobel Selecky | Director | MIXED | — | — |
| 2026-06-26 | Barry J. Simon | Director | Sell | — | — |
| 2026-06-10 | Wesley Clark | Director | A | — | — |
| 2026-06-10 | Cheryl Cohen | Director | A | — | — |
| 2026-06-10 | MICHAEL D BLASZYK | Director | A | — | — |
| 2026-06-10 | LINDA MAXWELL | Director | A | — | — |
| 2026-06-10 | Christobel Selecky | Director | A | — | — |
| 2026-06-10 | Bruce Wendel | Director | A | — | — |
| 2026-06-05 | Barry J. Simon | Director | Sell | — | — |
| 2026-04-02 | MP 13 Ventures, LLC | 10%+ Owner | C | — | — |
| 2026-02-26 | Barry J. Simon | Director | Sell | — | — |
| 2026-02-24 | REGAN J LAUER | Chief Accounting Officer | MIXED | — | — |
| 2026-02-24 | David C. Sachs | Chief Financial Officer | MIXED | — | — |
| 2026-02-24 | Barry J. Simon | Director | MIXED | — | — |
| 2026-02-24 | Richard Adcock | CEO & President | MIXED | — | — |
| 2026-02-24 | Christobel Selecky | Director | MIXED | — | — |
| 2026-02-24 | Nant Capital, LLC | 10%+ Owner | MIXED | — | — |
| 2026-02-12 | REGAN J LAUER | Chief Accounting Officer | MIXED | — | — |
| 2026-02-12 | Richard Adcock | CEO & President | MIXED | — | — |
| 2026-02-12 | David C. Sachs | Chief Financial Officer | MIXED | — | — |
| 2026-02-12 | PATRICK SOON-SHIONG | See remarks | MIXED | — | — |
| 2026-01-21 | Barry J. Simon | Director | Sell | — | — |
| 2026-01-21 | Christobel Selecky | Director | MIXED | — | — |
| 2026-01-05 | Richard Adcock | CEO & President | MIXED | — | — |
| 2026-01-05 | David C. Sachs | Chief Financial Officer | MIXED | — | — |
| 2025-12-16 | Bruce Wendel | Director | A | — | — |
| 2025-06-20 | Christobel Selecky | Director | A | — | — |
| 2025-06-20 | MICHAEL D BLASZYK | Director | A | — | — |
| 2025-06-20 | Wesley Clark | Director | A | — | — |
| 2025-06-20 | LINDA MAXWELL | Director | A | — | — |
| 2025-06-20 | Cheryl Cohen | Director | A | — | — |
| 2025-02-25 | David C. Sachs | Chief Financial Officer | MIXED | — | — |
| 2025-02-25 | Barry J. Simon | Director | MIXED | — | — |
| 2025-02-25 | Richard Adcock | CEO & President | MIXED | — | — |
| 2025-02-25 | REGAN J LAUER | Chief Accounting Officer | MIXED | — | — |
| 2025-02-25 | Nant Capital, LLC | 10%+ Owner | MIXED | — | — |
| 2025-02-12 | David C. Sachs | Chief Financial Officer | A | — | — |
| 2025-02-12 | PATRICK SOON-SHIONG | See remarks | A | — | — |
| 2025-02-12 | REGAN J LAUER | Chief Accounting Officer | A | — | — |
| 2025-02-12 | Richard Adcock | CEO & President | A | — | — |
| 2025-01-24 | Barry J. Simon | Director | M | — | — |
| 2025-01-03 | David C. Sachs | Chief Financial Officer | MIXED | — | — |
| 2025-01-03 | Richard Adcock | CEO & President | MIXED | — | — |
| 2024-12-16 | REGAN J LAUER | Chief Accounting Officer | MIXED | — | — |
| 2024-12-12 | MP 13 Ventures, LLC | 10%+ Owner | C | — | — |
| 2024-06-13 | John Owen Brennan | Director | A | — | — |
| 2024-06-13 | Christobel Selecky | Director | A | — | — |
| 2024-06-13 | Wesley Clark | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | See remarks | 291,526,126 | — |
| — | 10%+ Owner | 291,179,746 | — |
| — | 10%+ Owner | 77,315,845 | — |
| — | 10%+ Owner | 39,803,001 | — |
| — | 10%+ Owner | 37,857,346 | — |
| — | Director | 2,802,788 | — |
| — | CEO & President | 562,274 | — |
| — | Chief Financial Officer | 320,825 | — |
| — | Director | 265,582 | — |
| — | Director | 125,386 | — |
| — | Chief Accounting Officer | 117,548 | — |
| — | Director | 35,064 | — |
| — | Director | 25,000 | — |
| — | Director | 8,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IBRX quote page; the site-wide leaderboard is on the insider transactions hub.